Antibacterial activity of co-trimazine in vitro and in vivo.
Co-trimazine is a new drug combination especially designed for the treatment of urinary tract infections. It consists of trimethoprim (90 mg) and sulphadiazine (410 mg). When combined in vitro, the components show high activity and a high frequency of synergy against urinary tract pathogens. After oral absorption sulphadiazine has a serum half-life similar to that of trimethoprim and is excreted in active form into the urine to a much higher degree than sulphamethoxazole. The ratio of the concentrations of trimethoprim and sulphadiazine in the urine following co-trimazine is favourable for a strong synergistic action between the compounds. In cross-over studies in volunteers receiving repeated daily doses of co-trimazine, either 500 mg twice daily or 1000 mg once daily, it was found that antibacterial activity in the urine was at least as high as that provided by co-trimoxazole (2 x 960 mg) and considerably higher and more uniform than that given by nitrofurantion (3 x 50 mg).
D000042:Absorption; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D004341:Drug Evaluation; D004357:Drug Synergism; D006801:Humans; D066298:In Vitro Techniques; D007700:Kinetics; D008826:Microbial Sensitivity Tests; D009582:Nitrofurantoin / Q000378:metabolism / Q000494:pharmacology; D013411:Sulfadiazine / Q000378:metabolism / Q000494:pharmacology*; D013420:Sulfamethoxazole / Q000378:metabolism / Q000494:pharmacology; D013997:Time Factors; D014295:Trimethoprim / Q000378:metabolism / Q000494:pharmacology*; D014556:Urine / Q000382:microbiology
D004338:Drug Combinations; D013411:Sulfadiazine; D009582:Nitrofurantoin; D014295:Trimethoprim; D013420:Sulfamethoxazole